AtriCure, Inc. (ATRC)
$
32.2
-0.57 (-1.77%)
Key metrics
Financial statements
Free cash flow per share
0.0040
Market cap
1.6 Billion
Price to sales ratio
3.3792
Debt to equity
0.1703
Current ratio
4.1078
Income quality
-0.6039
Average inventory
75.1 Million
ROE
-0.0829
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, which are single-use disposable radio frequency products. It also provides multifunctional pens and linear ablation devices, such as the MAX Pen device that allows surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, stimulation, and ablate cardiac tissue with the same instrument. Additionally, the Coolrail device is designed for creating longer linear ablation lines. The cryoICE Cryoablation System enables users to perform linear ablations of varying lengths, while the EPi-Sense Guided Coagulation System serves as a single-use disposable device for addressing symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure's product lineup includes the AtriClip System, an implantable device used with a single-use disposable applier, and the LARIAT System, which provides a suture-based solution for soft-tissue closure that accommodates diverse anatomical shapes. The company also markets Lumitip Dissectors for tissue separation, Glidepath guides for clamp placement, Subtle Cannulas to enhance access for EPi-Sense catheters, and various reusable cardiac surgery instruments utilized in procedures for heart valve repair or replacement. The gross profit stands at $347,524,000.00 highlighting the company's profitability from core operations. The cost of revenue for the company is $117,783,000.00 showcasing its production and operational expenses. The company reported depreciation and amortization expenses of $18,733,000.00 reflecting the wear and tear of its assets. Furthermore, the company incurred an interest expense of $6,407,000.00 signifying its debt servicing obligations, and the operating expenses total $387,537,000.00 encompassing various operational costs incurred. In terms of market positioning, the stock is affordable at $32.20 making it an attractive option for budget-conscious investors. With an average trading volume of 567,455.00 the stock indicates moderate liquidity, providing a balanced trading experience for investors. The company has a market capitalization of $1,594,057,780.00 which classifies it as a small-cap player. AtriCure is a key player in the Medical - Instruments & Supplies industry, contributing significantly to the overall market landscape and belonging to the Healthcare sector, thereby driving innovation and growth within its field.
Investing in AtriCure, Inc. (ATRC) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
Analysts predict AtriCure, Inc. stock to fluctuate between $20.20 (low) and $43.11 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-07-01, AtriCure, Inc.'s market cap is $1,594,057,780, based on 49,504,900 outstanding shares.
Compared to Eli Lilly & Co., AtriCure, Inc. has a Lower Market-Cap, indicating a difference in performance.
To buy AtriCure, Inc. (ATRC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ATRC. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Revenue: $465,307,000 | EPS: -$0.95 | Growth: 43.94%.
Visit https://www.atricure.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $89.18 (2021-11-05) | All-time low: $18.94 (2024-06-18).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
a month ago
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference. AtriCure's management is scheduled to host a fireside chat on Monday, June 9, 2025, at 4:00 p.m. Eastern Standard Time. Interested parties may acc.
zacks.com
2 months ago
The consensus price target hints at a 54.7% upside potential for AtriCure (ATRC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
seekingalpha.com
2 months ago
AtriCure, Inc. (NASDAQ:ATRC ) Q1 2025 Earnings Conference Call April 29, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants William Plovanic - Canaccord Genuity Matthew O'Brien - Piper Sandler Companies John McAulay - Stifel Financial Corp. Lily Lozada - JPMorgan Chase & Co. Marie Thibault - BTIG, LLC Danny Stauder - Citizens JMP Securities, LLC Mike Matson - Needham & Company, LLC Danielle Antalffy - UBS Group AG Suraj Kalia - Oppenheimer & Co. Inc. Operator Good afternoon, and welcome to AtriCure's First Quarter 2025 Earnings Conference Call. This call is being recorded for replay purposes.
zacks.com
2 months ago
The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zacks.com
2 months ago
AtriCure (ATRC) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.25 per share a year ago.
businesswire.com
2 months ago
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2025 financial results. “Our performance in the first quarter reflects outstanding execution of several new product launches and the strength of our overall business,” said Michael Carrel, President and Chief Executive Officer at AtriCure. “As.
businesswire.com
3 months ago
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2025 financial results on Tuesday, April 29, 2025. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, April 29, 2025, to discuss its first quarter 2025 financial results. Those interested in list.
businesswire.com
4 months ago
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today reaffirmed that the company will host an Analyst & Investor Day at its headquarters in Mason, Ohio on Wednesday, March 26, 2025 from 1:00 pm to 4:00 pm ET. “Our team is excited to highlight our leading portfolio of products and innovative pipeline for market expa.
zacks.com
5 months ago
AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
seekingalpha.com
5 months ago
AtriCure, Inc. (NASDAQ:ATRC ) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lily Lozada - JPMorgan William Plovanic - Canaccord Matthew O'Brien - Piper Sandler Marie Thibault - BTIG Rick Wise - Stifel Mike Matson - Needham & Company Danny Stauder - Citizens JMP Danielle Antalffy - UBS Suraj Kalia - Oppenheimer Matthew O'Brien - Piper Sandler Operator Good afternoon, and welcome to AtriCure's Fourth Quarter and Full Year 2024 Earnings Conference Call. This call is being recorded for replay purposes.
See all news